From single- to multi-target drugs in cancer therapy When aspecificity becomes an advantage Pages on BioPortfolio:

BioPortfolio - Molecular Oncology
Recent Search Terms used to find this page: From single- to multi-target drugs in cancer therapy When aspecificity becomes an advantage pdf | From single- ...
http://www.bioportfolio.com/biocorporate/7197-Molecular+Onco...

Results from other life science and pharmaceutical sites:

From single- to multi-target drugs in cancer therapy: when ...
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Petrelli A, Giordano S. Division of Molecular Oncology, ...
http://www.ncbi.nlm.nih.gov/pubmed/18288997...

Network pharmacology: the next paradigm in drug discovery ...
1 Nov 2008 ... S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr. Med. Chem. 15, 422–432 (2008). ...
http://www.nature.com/uidfinder/10.1038/nchembio.118...

("N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl ...
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Petrelli A, Giordano S. Curr Med Chem. 2008;15(5):422-32. ...
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Detai...

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic ...
Petrelli, A. & Giordano, S. From single- to multi-target drugs in cancer therapy : when aspecificity becomes an advantage. Curr. Med. Chem. ...
http://www.nature.com/nrc/journal/v9/n1/full/nrc2545.html...

Combination of target agents: challenges and oppor...[J Thorac ...
2006]; From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. [Curr Med Chem. 2008]; Second-line treatment of ...
http://www.ncbi.nlm.nih.gov/pubmed/17457232...

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.